LAVAL, Quebec, April 1, 2015 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today
announced it has completed the previously announced acquisition of
Salix Pharmaceuticals, Ltd. Salix Pharmaceuticals is a specialty
pharmaceutical company that offers innovative gastroenterology
treatments such as XIFAXAN® (rifaximin)
550 mg, RUCONEST® (C1 esterase inhibitor
[recombinant]), APRISO® (mesalamine),
UCERIS® (budesonide) extended release tablets
and RELISTOR® (methylnaltrexone bromide).
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, eye health, neurology, and
branded generics. More information about Valeant Pharmaceuticals
International, Inc. can be found at www.valeant.com.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-international-inc-completes-acquisition-of-salix-pharmaceuticals-300059279.html
SOURCE Valeant Pharmaceuticals International, Inc.